Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2013

Conditions
GlioblastomaBrain Tumor
Interventions
DRUG

Sunitinib

Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Pfizer

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00864864 - Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter